Literature DB >> 8331476

Mutants of Toxoplasma gondii resistant to atovaquone (566C80) or decoquinate.

E R Pfefferkorn1, S E Borotz, R F Nothnagel.   

Abstract

Mutants of Toxoplasma gondii resistant to drugs that appear to affect the mitochondrial bc1 complex were isolated with the aid of mutagenesis with ethylnitrosourea. Mutant DeqR-1 was > 1,000-fold more resistant to decoquinate than was the wild type but more sensitive to atovaquone (formerly called 566C80). Mutant AtoR-1 was 20-fold more resistant to atovaquone than was the wild type and was also partially cross-resistant to decoquinate. Both drugs rapidly inhibited oxygen uptake by freshly prepared extracellular parasites, and the mutants were resistant to this inhibition. Neither the addition of uracil to the medium nor the use of a mutant of T. gondii with a defect in pyrimidine salvage had a substantial effect on the in vitro anti-parasitic activity of these drugs, suggesting that de novo pyrimidine synthesis was not the major biochemical target of either drug.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8331476

Source DB:  PubMed          Journal:  J Parasitol        ISSN: 0022-3395            Impact factor:   1.276


  14 in total

1.  Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.

Authors:  N Schöler; K Krause; O Kayser; R H Müller; K Borner; H Hahn; O Liesenfeld
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 2.  Drug target identification in protozoan parasites.

Authors:  Joachim Müller; Andrew Hemphill
Journal:  Expert Opin Drug Discov       Date:  2016-06-16       Impact factor: 6.098

3.  Structure-activity relationships of Toxoplasma gondii cytochrome bc1 inhibitors.

Authors:  P Holland Alday; Aaron Nilsen; J Stone Doggett
Journal:  Expert Opin Drug Discov       Date:  2022-08-08       Impact factor: 7.050

4.  Frequency of drug resistance in Plasmodium falciparum: a nonsynergistic combination of 5-fluoroorotate and atovaquone suppresses in vitro resistance.

Authors:  S Gassis; P K Rathod
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

5.  In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.

Authors:  Pascale Meneceur; Marie-Anne Bouldouyre; Dominique Aubert; Isabelle Villena; Jean Menotti; Virginie Sauvage; Jean-François Garin; Francis Derouin
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

Review 6.  Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

Review 7.  Development of forward genetics in Toxoplasma gondii.

Authors:  L David Sibley
Journal:  Int J Parasitol       Date:  2009-02-28       Impact factor: 3.981

8.  Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis.

Authors:  O Djurković-Djaković; T Nikolić; F Robert-Gangneux; B Bobić; A Nikolić
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

9.  Real-Time Analysis of Mitochondrial Electron Transport Chain Function in Toxoplasma gondii Parasites Using a Seahorse XFe96 Extracellular Flux Analyzer.

Authors:  Jenni A Hayward; Esther Rajendran; F Victor Makota; Brad J Bassett; Michael Devoy; Teresa Neeman; Giel G van Dooren
Journal:  Bio Protoc       Date:  2022-01-05

10.  Lack of mitochondrial MutS homolog 1 in Toxoplasma gondii disrupts maintenance and fidelity of mitochondrial DNA and reveals metabolic plasticity.

Authors:  Tamila Garbuz; Gustavo Arrizabalaga
Journal:  PLoS One       Date:  2017-11-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.